Loading clinical trials...
Loading clinical trials...
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Canakinumab
Placebo
Locations
283
United States
Highlands Oncology Group .
Fayetteville, Arkansas, United States
Cancer and Blood Specialty Clinic
Los Alamitos, California, United States
University of California at Los Angeles
Los Angeles, California, United States
VA Palo Alto Health Care System CRLX030A2301
Palo Alto, California, United States
Sansum Clinic
Santa Barbara, California, United States
Rocky Mountain Cancer Centers Denver-Mdtn(Bone&MarrowTransp)
Longmont, Colorado, United States
Start Date
March 16, 2018
Primary Completion Date
March 17, 2022
Completion Date
February 7, 2023
Last Updated
October 9, 2024
NCT07431827
NCT06758401
NCT06427941
NCT06476808
NCT07164313
NCT05142189
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions